LOS ANGELES (Reuters) - Merck & Co. Inc.'s experimental HIV drug in a new class called integrase inhibitors can control the virus in nearly 80 percent of previously treated patients, when combined ...
Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...
Researchers from the U.S. National Institutes of Health and collaborators recently conducted a study investigating the mechanisms of HIV-1 resistance to integrase strand transfer inhibitors (INSTIs), ...
The findings confirm that allosteric inhibition of integrase is clinically viable, validating a new antiviral drug class.
BioWorld - Sunday, September 17, 2023 Breaking News: Try BioWorld for free for two weeks See today's BioWorld Science Home » NIAID grant supports development of ultra-long-acting HIV integrase ...
(RTTNews) - ViiV Healthcare announced an exclusive collaboration and license agreement with Shionogi & Co. Ltd. for S-365598, an investigational integrase strand transfer inhibitor with potential for ...
SAN FRANCISCO--(BUSINESS WIRE)--Exavir Therapeutics, a company dedicated to transforming the lives of patients with chronic viral infections and CNS disorders with ultra-long-acting therapeutics, ...
They did not find an increased risk of MACE (HR: 1.03, 95% CI: 0.63, 1.52). Researchers noted that it will be important for future studies to determine whether taking integrase inhibitors leads to ...
Please provide your email address to receive an email when new articles are posted on . In a Healio video exclusive, Edward V. Loftus Jr., MD, discusses the potential of tumor necrosis factor-like ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback